Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 80%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation

Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

It is very uncertain whether transarterial embolisation plus radiofrequency ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
OR 2.11 [0.18, 25.35]
2 studies · 84 participants
Very low

Transarterial embolisation plus percutaneous alcohol injection vs percutaneous alcohol injection

Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes serious adverse events (number of participants) compared with percutaneous alcohol injection (very low certainty).

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
OR 5.41 [0.25, 118.34]
1 study · 52 participants
Very low

Laser ablation vs radiofrequency ablation

Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

It is very uncertain whether laser ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
OR 1 [0.06, 16.31]
2 studies · 170 participants
Very low

Surgery vs radiofrequency ablation

Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery

Surgery may leads to higher serious adverse events (number of participants) compared with radiofrequency ablation (low certainty).

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
OR 17.96 [2.28, 141.6]
1 study · 120 participants
Low

Percutaneous ethanol injection vs radiofrequency ablation

Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).

1 finding from 1 review

Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
OR 0.67 [0.19, 2.4]
3 studies · 365 participants
Very low